Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,767 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,767 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $11.02, for a total transaction of $19,472.34. Following the completion of the sale, the senior vice president owned 76,918 shares of the company’s stock, valued at $847,636.36. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Celia Eckert also recently made the following trade(s):

• On Thursday, March 5th, Celia Eckert sold 3,244 shares of Xencor stock. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The stock was sold at an average price of $11.90, for a total value of $17,754.80.

Xencor Stock Performance

XNCR traded up $0.55 during midday trading on Monday, reaching $11.87. The company’s stock had a trading volume of 835,908 shares, compared to its average volume of 711,120. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The company has a fifty day simple moving average of $12.79 and a 200 day simple moving average of $13.00. The stock has a market cap of $870.55 million, a P/E ratio of -9.57 and a beta of 0.95. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.55. The company had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor’s revenue for the quarter was down 46.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.62) earnings per share. Research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

A number of hedge funds and other institutional investors have recently made changes to their positions in XNCR. BVF Inc. IL lifted its holdings in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock worth $14,932,000 after purchasing an additional 1,092,095 shares in the last quarter. State Street Corp increased its stake in Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after buying an additional 833,423 shares during the last quarter. Primecap Management Co. CA lifted its position in Xencor by 7.9% during the 2nd quarter. Primecap Management Co. CA now owns 10,527,322 shares of the biopharmaceutical company’s stock worth $82,745,000 after buying an additional 766,310 shares in the last quarter. Finally, Jefferies Financial Group Inc. increased its position in shares of Xencor by 620.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after acquiring an additional 620,440 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Barclays raised their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Truist Financial assumed coverage on shares of Xencor in a research report on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective for the company. Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.